CSL (ASX:CSL) - Stock Price, News & Analysis

CSL Stock Overview

CSL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 23.2% below our estimate of its fair value

Earnings are forecast to grow 14.72% per year

Earnings grew by 16.7% over the past year

Risk Analysis

Has a high level of debt

CSL Limited Competitors

Clinuvel Pharmaceuticals

ASX:CUV

AU$766.1m

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$101.7b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$96.1b

Gilead Sciences

NasdaqGS:GILD

US$82.5b

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share Price	AU$271.40
52 Week High	AU$312.99
52 Week Low	AU$228.65
Beta	0.29
1 Month Change	-2.78%
3 Month Change	-6.09%
1 Year Change	-9.49%
3 Year Change	-0.51%
5 Year Change	39.18%
Change since IPO	33,825.34%

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 19

Recent updates

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Oct 26

We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation

Oct 05

Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

Sep 02

CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate

Jul 22

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

Jul 01

Do CSL's (ASX:CSL) Earnings Warrant Your Attention?

May 20

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Mar 29

Shareholder Returns

	CSL	AU Biotechs	AU Market
7D	-3.2%	-3.8%	-3.1%
1Y	-9.5%	-8.7%	4.0%

Return vs Industry: CSL matched the Australian Biotechs industry which returned -8.7% over the past year.

Return vs Market: CSL underperformed the Australian Market which returned 4% over the past year.

Price Volatility

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.5%
Biotechs Industry Average Movement	11.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: CSL has not had significant price volatility in the past 3 months.

Volatility Over Time: CSL's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1916	32,065	Paul McKenzie	www.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSL fundamental statistics
Market cap	AU$131.15b
Earnings (TTM)	AU$3.85b
Revenue (TTM)	AU$22.08b

34.1x

P/E Ratio

5.9x

P/S Ratio

Is CSL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSL income statement (TTM)
Revenue	US$14.18b
Cost of Revenue	US$6.86b
Gross Profit	US$7.32b
Other Expenses	US$4.85b
Earnings	US$2.47b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 13, 2024

Earnings per share (EPS)	5.12
Gross Margin	51.63%
Net Profit Margin	17.43%
Debt/Equity Ratio	54.4%

How did CSL perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

48%

Payout Ratio

CSL Stock Overview

Rewards

Risk Analysis

CSL Limited Competitors

ASX:CUV

AU$766.1m

NasdaqGS:VRTX

US$101.7b

NasdaqGS:REGN

US$96.1b

NasdaqGS:GILD

US$82.5b

Price History & Performance

Recent News & Updates

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

Recent updates

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued